The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Context of Aneurysmal Subarachnoid Hemorrhage (aSAH)-A Prospective Observational Study.
delayed cerebral infarction (DCI)
inflammation
outcome predictability
soluble urokinase plasminogen activator receptor (suPAR)
subarachnoid hemorrhage (SAH)
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
12
2021
accepted:
31
01
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Outcome after aneurysmal subarachnoid hemorrhage (aSAH) is highly variable and largely determined by early brain injury and delayed cerebral ischemia (DCI). Soluble urokinase plasminogen activator receptor (suPAR) represents a promising inflammatory marker which has previously been associated with outcome in traumatic brain injury and stroke patients. However, its relevance in the context of inflammatory changes after aSAH is unclear. Here, we aimed to characterize the role of circulating suPAR in both serum and cerebrospinal fluid (CSF) as a novel biomarker for aSAH patients. A total of 36 aSAH patients, 10 control patients with unruptured abdominal aneurysm and 32 healthy volunteers were included for analysis. suPAR was analyzed on the day of admission in all patients. In aSAH patients, suPAR was also determined on the day of DCI and the respective time frame in asymptomatic patients. One- and two-sample Significantly elevated suPAR serum levels (suPAR-SL) on admission were found for aSAH patients compared to healthy controls, but not compared to vascular control patients. Disease severity as documented according to Hunt and Hess grade and modified Fisher grade was associated with higher suPAR CSF levels (suPAR-CSFL). In aSAH patients, suPAR-SL increased daily by 4%, while suPAR-CSFL showed a significantly faster daily increase by an average of 22.5% per day. Each increase of the suPAR-SL by 1 ng/ml more than tripled the odds of developing DCI (OR = 3.06). While admission suPAR-CSFL was not predictive of DCI, we observed a significant correlation with modified Rankin's degree of disability at discharge. Elevated suPAR serum level on admission as a biomarker for early inflammation after aSAH is associated with an increased risk of DCI. Elevated suPAR-CSFL levels correlate with a higher degree of disability at discharge. These distinct relations and the observation of a continuous increase over time affirm the role of inflammation in aSAH and require further study.
Identifiants
pubmed: 35359651
doi: 10.3389/fneur.2022.841024
pmc: PMC8960720
doi:
Types de publication
Journal Article
Langues
eng
Pagination
841024Informations de copyright
Copyright © 2022 Schmidt, Albanna, Weiss, Veldeman, Conzen, Nikoubashman, Blume, Kluger, Clusmann, Loosen and Schubert.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Neurosurg. 2020 Sep 4;:1-9
pubmed: 32886914
Neurosurgery. 2015 Nov;77(5):786-92; discussion 792-3
pubmed: 26280117
Acta Neurol Scand. 2021 Feb;143(2):195-205
pubmed: 32990943
Nat Commun. 2020 Jun 25;11(1):3218
pubmed: 32587239
Neurocrit Care. 2010 Dec;13(3):339-46
pubmed: 20725805
Int J Mol Sci. 2016 Apr 02;17(4):497
pubmed: 27049383
Stroke. 2018 Mar;49(3):693-699
pubmed: 29438081
N Engl J Med. 2017 Jul 20;377(3):257-266
pubmed: 28723321
World Neurosurg. 2017 Aug;104:152-157
pubmed: 28512045
Neurocrit Care. 2014 Dec;21 Suppl 2:S148-58
pubmed: 25208673
Stroke. 2010 Oct;41(10):2391-5
pubmed: 20798370
Acta Neurochir (Wien). 2012 Mar;154(3):397-404
pubmed: 22134501
Neurology. 2010 May 11;74(19):1486-7
pubmed: 20410463
J Neurol Neurosurg Psychiatry. 1981 Apr;44(4):285-93
pubmed: 6453957
Front Neurol. 2019 Feb 21;10:136
pubmed: 30858818
Lab Invest. 1999 Jun;79(6):717-22
pubmed: 10378514
Scand J Infect Dis. 2004;36(1):14-9
pubmed: 15000553
Neurocrit Care. 2014 Dec;21 Suppl 2:S282-96
pubmed: 25501689
Stroke. 2015 Oct;46(10):3014-9
pubmed: 26152299
Microcirculation. 2019 Apr;26(3):e12516
pubmed: 30431201
Neurosurgery. 2017 Jun 1;80(6):942-949
pubmed: 28201539
Circulation. 2017 Aug 29;136(9):787-797
pubmed: 28720724
Front Neurol. 2020 Jun 03;11:439
pubmed: 32582003
Front Neurol. 2017 Apr 18;8:144
pubmed: 28458650
Clin Neurol Neurosurg. 2015 Nov;138:177-83
pubmed: 26355810
BMC Med. 2012 Jan 05;10:2
pubmed: 22221662
Acta Clin Belg. 2021 Feb;76(1):79-84
pubmed: 31434557
Stroke. 2002 May;33(5):1225-32
pubmed: 11988595
Exp Neurol. 2021 Feb;336:113535
pubmed: 33249033
Curr Atheroscler Rep. 2017 Oct 23;19(12):50
pubmed: 29063300
Stroke. 2007 Aug;38(8):2315-21
pubmed: 17569871
J Clin Neurophysiol. 2016 Jun;33(3):174-82
pubmed: 27258440
Expert Rev Cardiovasc Ther. 2015;13(9):975-87
pubmed: 26308600
J Neurosurg. 2019 Aug 23;:1-9
pubmed: 31443072
Front Neurol. 2017 Oct 23;8:555
pubmed: 29109695
Cerebrovasc Dis. 2013;35(2):93-112
pubmed: 23406828
AJR Am J Roentgenol. 2018 Oct;211(4):891-895
pubmed: 30085836
Curr Opin Neurol. 2019 Feb;32(1):49-53
pubmed: 30516639
J Neurol Neurosurg Psychiatry. 2001 Mar;70(3):340-3
pubmed: 11181855
J Neurosurg. 1989 Nov;71(5 Pt 1):741-6
pubmed: 2809729
Oncotarget. 2018 Jun 05;9(43):27027-27038
pubmed: 29930748
J Cereb Blood Flow Metab. 2012 Feb;32(2):203-12
pubmed: 22146193
In Vivo. 2017 May-Jun;31(3):381-386
pubmed: 28438866
J Cereb Blood Flow Metab. 2017 Nov;37(11):3625-3634
pubmed: 28112024
Carcinogenesis. 2019 Aug 22;40(8):947-955
pubmed: 30805627
Curr Neurol Neurosci Rep. 2019 Aug 29;19(10):78
pubmed: 31468197
World Neurosurg. 2018 Jul;115:234-244
pubmed: 29709752
Science. 2006 Feb 3;311(5761):656-9
pubmed: 16456079
J Clin Med. 2020 May 31;9(6):
pubmed: 32486367
Neurol India. 2014 Sep-Oct;62(5):498-502
pubmed: 25387618